The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
As a result of illegal tactics, including illegal surveillance and vigilantism, used by the RCMP Security Service and the consequent scandals surrounding the RCMP, intelligence work was transferred to a new agency, CSIS in 1984 through the implementation of Bill C-9.
== External links == Media related to Stigmata at Wikimedia Commons Stigmata, Chapter 5: Arguments for the Existence of God Based on Experience, by Dr. Philip A. Pecorino (2001). Queens Borough Community College.
Thereafter, the amount of carbon-14 in organic matter decreases according to decay processes that may also be independently cross-checked by other means (such as checking the carbon-14 in individual tree rings, for example).
The world's largest producers of ethylene oxide are Dow Chemical Company (3–3.5 Mt (3.3–3.9 million short tons) in 2006), Saudi Basic Industries (2,000–2,500 tonnes (2,200–2,800 short tons) in 2006), Royal Dutch Shell (1.328 Mt (1.464 million short tons) in 2008–2009), BASF (1.175 Mt (1.295 million short tons) in 2008–2009), China Petrochemical Corporation (~1 Mt (1.1 million short tons) in 2006), Formosa Plastics (~1 Mt (1.1 million short tons) in 2006), and Ineos (0.92 Mt (1.01 million short tons) in 2008–2009).
Deborah Levy (born 6 August 1959); novelist, playwright and poet of South African and Lithuanian Jewish ancestry; her plays were staged by the Royal Shakespeare Company; novels included Beautiful Mutants, Swallowing Geography and Billy & Girl; recent fiction has included the Booker-shortlisted novels Swimming Home and Hot Milk, as well as the Booker-longlisted The Man Who Saw Everything and short-story collection Black Vodka;The Guardian ranked The Cost of Living number 84 in list of "The 100 best books of the 21st century". Gertrude Rachel Levy (5 November 1883 – 10 October 1966), author and cultural historian writing about comparative mythology, matriarchy, epic poetry and archaeology; worked with Department of Antiquities in Mandatory Palestine. Paul Levy, food writer, biographer; long rabbinical pedigree Bernard Lewis (31 May 1916 – 19 May 2018); specialised in Oriental studies; public intellectual and political commentator; wrote over ten books on history of Islam and the interaction between Islam and the West; was called "the West's leading interpreter of the Middle East". Others have accused Lewis of having revived the image of cultural inferiority of Islam and of emphasising the dangers of jihad. His advice was frequently sought by neoconservative policymakers, including the Bush administration. However, his active support of the Iraq War and neoconservative ideals have since come under scrutiny. Maureen Lipman, (born 10 May 1946) is an English actress, columnist and comedian, who has published several collections of her comedy sketches, and autobiography.
Sources: en.wikipedia.org
In contrast to ALP, levels of ALT, AST, GGT, and lactate dehydrogenase are only slightly changed or largely unchanged during pregnancy. Bilirubin levels are significantly decreased in pregnancy. In pregnancy conditions such as hyperemesis gravdirum, ALP levels can reach 215 IU/L, meanwhile, in pre-eclampsia, ALP can reach 14 IU/L, and in HELLP syndrome ALP levels can reach 15 IU/L.
== Use in antibody-drug conjugates == A new antibody-drug conjugate (ADC) technology based on α-amanitin has shown activity in therapy-resistant tumor cells, e.g. cells expressing multi-drug resistant transporters, tumor-initiating cells and non-dividing cells at picomolar concentrations. The unique mode of action of α-amanitin seems to make the amanitin-based ADCs a suitable toxic payload. This toxin has a water-soluble structure, resulting in ADCs with low tendency for aggregation. Significant clinical advances occurred in 2025 and 2026 with Heidelberg Pharma’s lead candidate HDP-101 (pamlectabart tismanitin), a BCMA-targeted amanitin-based antibody-drug conjugate (ATAC) for relapsed or refractory multiple myeloma. In the ongoing Phase I/IIa trial (NCT04879043), dose escalation proceeded safely up to 218 µg/kg without reaching a maximum tolerated dose, and the recommended Phase IIa dose was selected in April 2026. The program received FDA Fast Track designation in October 2025. In the higher-dose cohorts (90–140 µg/kg), overall response rates reached 38–57 %, with several heavily pretreated patients, including those who had failed prior BCMA-directed therapies, achieving stringent complete remissions lasting more than one year. The safety profile remained favorable, with mostly mild-to-moderate and manageable adverse events and no clinically relevant hepatotoxicity, ocular toxicity, or renal impairment.
=== Other anxiety disorders === Sertraline has been successfully used for the treatment of social anxiety disorder. All three major domains of the disorder (fear, avoidance, and physiological symptoms) respond to sertraline. Maintenance treatment, after the response is achieved, prevents the return of the symptoms. The improvement is greater among the patients with later, adult onset of the disorder. In a comparison trial, sertraline was superior to exposure therapy, but patients treated with the psychological intervention continued to improve during a year-long follow-up, while those treated with sertraline deteriorated after treatment termination. The combination of sertraline and cognitive behavioral therapy appears to be more effective in children and young people than either treatment alone. Sertraline has not been approved for the treatment of generalized anxiety disorder; however, several guidelines recommend it as a first-line medication referring to good quality controlled clinical trials.
=== United Kingdom === From 2013, the UK National Health Service (NHS) started offering shingles vaccination to elderly people. People aged either 70 or 79 on 1 September 2013, were offered the vaccine. People aged 71 to 78 on that date would only have an opportunity to have the shingles vaccine after reaching the age of 79. The original intention was for people aged between 70 and 79 to be vaccinated, but the NHS later said that the vaccination program was being staggered as it would be impractical to vaccinate everyone in their 70s in a single year. In 2021, vaccination against shingles is available on the NHS to people aged 70 to 79. Vaccination is with single-dose Zostavax, except for people for whom Zostavax is deemed unsuitable, for example, with a condition that affects the immune system, for whom two-dose Shingrix vaccine is recommended. The NHS stated "The shingles vaccine is not available on the NHS to anyone aged 80 or over because it seems to be less effective in this age group". Since 2023, the shingles vaccines is being offered to healthy people turning 65.
Sources: en.wikipedia.org
Annals of Clinical Biochemistry is a bimonthly peer-reviewed scientific journal covering all aspects of clinical biochemistry. The editor-in-chief is Michael J Murphy (University of Dundee). It was established 1960 and is published by SAGE Publications on behalf of The Association for Clinical Biochemistry and Laboratory Medicine.
Field desorption refers to an ion source in which a high-potential electric field is applied to an emitter with a sharp surface, such as a razor blade, or more commonly, a filament from which tiny "whiskers" have formed. This results in a very high electric field which can result in ionization of gaseous molecules of the analyte. Mass spectra produced by FI have little or no fragmentation. They are dominated by molecular radical cations M+. and less often, protonated molecules [M + H]+
Unlike other DOx drugs like DOM, DOPR, DOBU, and DOAM, 2,5-DMA does not produce hyperlocomotion in rodents and instead dose-dependently produces only hypolocomotion. On the other hand, it does similarly produce hypothermia at higher doses. Though 2,5-DMA appears to be inactive or of very low potency as a psychedelic in humans, it is a highly potent anti-inflammatory drug similarly to other DOx and 2C drugs. This was in spite of it being of very low potency as a serotonin 5-HT2A receptor agonist in terms of calcium mobilization in the study (EC50 = 3,548 nM; Emax = 109.0%). Based on the preceding findings, Charles D. Nichols has said that both fully anti-inflammatory non-psychedelic compounds like 2,5-DMA and fully psychedelic non-anti-inflammatory compounds like DOTFM are known.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.